Supplementary table 1. Comparison of clinical characteristics between patients with and without progressive disease (PD)

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Patients with PD | Patients without PD | P value |
|  | (n = 197) | (n = 124) |  |
| Age, years (mean±SD) | 50.37±12.51 | 53.73±11.28 | 0.142 |
| Gender |  |  | 0.709 |
| Male | 172 (87.3%) | 110 (88.7%) |  |
| Female | 25 (12.7%) | 14 (11.3%) |  |
| BCLC stage |  |  | 0.574 |
| B | 50 (25.4%) | 35 (28.2%) |  |
| C | 147 (74.6%) | 89 (71.8%) |  |
| ALBI grade |  |  | 0.835 |
| I | 90 (45.7%) | 56 (45.2%) |  |
| II | 104 (52.8%) | 67 (54.0%) |  |
| III | 3 (1.5%) | 1 (0.8%) |  |
| AFP, ng/ml |  |  | 0.005 |
| ≤ 400 | 83 (42.1%) | 72 (58.1%) |  |
| > 400 | 114 (57.9%) | 52 (41.9%) |  |
| Treatment modality |  |  | 0.340 |
| AP alone | 26 (13.2%) | 10 (8.1%) |  |
| AP with TKIs | 35 (17.8%) | 19 (15.3%) |  |
| AP with LT | 57 (28.9%) | 45 (36.3%) |  |
| AP with TKIs and LT | 79 (40.1%) | 50 (40.3%) |  |

SD, standard deviation; BCLC, Barcelona Clinic Liver Cancer; ALBI, albumin-bilirubin grade; AFP, alpha fetoprotein; AP, anti-PD-1 immunotherapy; TKIs, tyrosine kinase inhibitors; LT, locoregional therapy.